标题
Future directions in obesity pharmacotherapy
作者
关键词
Obesity, Pharmacotherapy, Glucagon-Like Peptide 1, Appetite, Weight loss, Islet Amyloid Polypeptide, Body Weight Maintenance, Energy metabolism, Type 2 diabetes
出版物
European Journal of Internal Medicine
Volume 93, Issue -, Pages 13-20
出版商
Elsevier BV
发表日期
2021-05-22
DOI
10.1016/j.ejim.2021.04.024
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
- (2020) Michael Ritchie et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
- (2020) Tina K. Thethi et al. DIABETES OBESITY & METABOLISM
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- (2019) V. R Aroda et al. DIABETES & METABOLISM
- GLP-1’s role in neuroprotection: a systematic review
- (2019) Damla Erbil et al. BRAIN INJURY
- SCO‐792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice
- (2019) Hiroaki Yashiro et al. DIABETES OBESITY & METABOLISM
- The Discovery and Development of Liraglutide and Semaglutide
- (2019) Lotte Bjerre Knudsen et al. Frontiers in Endocrinology
- An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
- (2019) Chen-Hsiu Lin et al. EXPERT OPINION ON PHARMACOTHERAPY
- New drugs for NAFLD: lessons from basic models to the clinic
- (2019) Katharina C. Reimer et al. Hepatology International
- Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs
- (2019) Awadhesh Kumar Singh et al. Expert Review of Clinical Pharmacology
- Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents
- (2018) David R. Saxon et al. DRUGS
- Gut hormone polyagonists for the treatment of type 2 diabetes
- (2018) Sara J. Brandt et al. PEPTIDES
- Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity
- (2018) Christina Neuner Boyle et al. Molecular Metabolism
- OUP accepted manuscript
- (2018) AGE AND AGEING
- The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases
- (2018) Vicky W.W. Tsai et al. Cell Metabolism
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Obesity: GDF15 tells the brain to lose weight
- (2017) M. Teresa Villanueva NATURE REVIEWS DRUG DISCOVERY
- KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight
- (2016) Sofie Gydesen et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records
- (2015) Alison Fildes et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure
- (2015) Jonatan Ising Bagger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2015) Laura J Carbone et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Does salmon calcitonin cause cancer? A review and meta-analysis
- (2015) G. Wells et al. OSTEOPOROSIS INTERNATIONAL
- Serum Levels of Human MIC-1/GDF15 Vary in a Diurnal Pattern, Do Not Display a Profile Suggestive of a Satiety Factor and Are Related to BMI
- (2015) Vicky Wang-Wei Tsai et al. PLoS One
- Treat-to-target trials: uses, interpretation and review of concepts
- (2013) A. J. Garber DIABETES OBESITY & METABOLISM
- Expression of concern—Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
- (2013) The Lancet Editors LANCET
- Food and Drug Administration's Obesity Drug Guidance Document
- (2012) Eric Colman CIRCULATION
- Glucagon-Like Peptide-1 and its Cardiovascular Effects
- (2012) Kyung-Sun Heo et al. Current Atherosclerosis Reports
- The Role of Pramlintide for Weight Loss
- (2010) Kaelen C Dunican et al. ANNALS OF PHARMACOTHERAPY
- Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
- (2010) Jody Dushay et al. GASTROENTEROLOGY
- The role of peptide YY in appetite regulation and obesity
- (2008) Efthimia Karra et al. JOURNAL OF PHYSIOLOGY-LONDON
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started